<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35388167</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2399-3642</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>5</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
              <Day>06</Day>
            </PubDate>
          </JournalIssue>
          <Title>Communications biology</Title>
          <ISOAbbreviation>Commun Biol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Simultaneous triple-parametric optical mapping of transmembrane potential, intracellular calcium and NADH for cardiac physiology assessment.</ArticleTitle>
        <Pagination>
          <StartPage>319</StartPage>
          <MedlinePgn>319</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">319</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s42003-022-03279-y</ELocationID>
        <Abstract>
          <AbstractText>Investigation of the complex relationships and dependencies of multiple cellular processes that govern cardiac physiology and pathophysiology requires simultaneous dynamic assessment of multiple parameters. In this study, we introduce triple-parametric optical mapping to simultaneously image metabolism, electrical excitation, and calcium signaling from the same field of view and demonstrate its application in the field of drug testing and cardiovascular research. We applied this metabolism-excitation-contraction coupling (MECC) methodology to test the effects of blebbistatin, 4-aminopyridine and verapamil on cardiac physiology. While blebbistatin and 4-aminopyridine alter multiple aspects of cardiac function suggesting off-target effects, the effects of verapamil were on-target and it altered only one of ten tested parameters. Triple-parametric optical mapping was also applied during ischemia and reperfusion; and we identified that metabolic changes precede the effects of ischemia on cardiac electrophysiology.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>George</LastName>
            <ForeName>Sharon A</ForeName>
            <Initials>SA</Initials>
            <Identifier Source="ORCID">0000-0001-9003-1158</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Engineering, The George Washington University, Washington, DC, USA. sharonann.george@northwestern.edu.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Engineering, Northwestern University, Chicago, IL, USA. sharonann.george@northwestern.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lin</LastName>
            <ForeName>Zexu</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Engineering, The George Washington University, Washington, DC, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Efimov</LastName>
            <ForeName>Igor R</ForeName>
            <Initials>IR</Initials>
            <Identifier Source="ORCID">0000-0002-1483-5039</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Engineering, The George Washington University, Washington, DC, USA. igor.efimov@northwestern.edu.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Engineering, Northwestern University, Chicago, IL, USA. igor.efimov@northwestern.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R44 HL139248</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>06</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Commun Biol</MedlineTA>
        <NlmUniqueID>101719179</NlmUniqueID>
        <ISSNLinking>2399-3642</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0U46U6E8UK</RegistryNumber>
          <NameOfSubstance UI="D009243">NAD</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>BH3B64OKL9</RegistryNumber>
          <NameOfSubstance UI="D015761">4-Aminopyridine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>CJ0O37KU29</RegistryNumber>
          <NameOfSubstance UI="D014700">Verapamil</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>SY7Q814VUP</RegistryNumber>
          <NameOfSubstance UI="D002118">Calcium</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D015761" MajorTopicYN="N">4-Aminopyridine</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000200" MajorTopicYN="N">Action Potentials</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002118" MajorTopicYN="Y">Calcium</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008564" MajorTopicYN="N">Membrane Potentials</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009243" MajorTopicYN="Y">NAD</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014700" MajorTopicYN="N">Verapamil</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>7</Day>
          <Hour>5</Hour>
          <Minute>29</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35388167</ArticleId>
        <ArticleId IdType="pmc">PMC8987030</ArticleId>
        <ArticleId IdType="doi">10.1038/s42003-022-03279-y</ArticleId>
        <ArticleId IdType="pii">10.1038/s42003-022-03279-y</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Ravens U. Sex differences in cardiac electrophysiology. Can. J. Physiol. Pharmacol. 2018;96:985–990.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30001496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>George, S. A., Lin, Z. &amp; Efimov, I. R. in Management of Cardiac Arrhythmias (eds. Yan, G., Kovey, P. R. &amp; Antzelevitch, C.) Ch. 1 (Humana Press, 2020).</Citation>
        </Reference>
        <Reference>
          <Citation>Efimov I, Nikolski V, Salama G. Optical imaging of the heart. Circ. Res. 2004;95:21–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15242982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>George SA, Efimov IR. Optocardiography: a review of its past, present, and future. Curr. Opin. Biomed. Eng. 2019;9:74–80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6892455</ArticleId>
            <ArticleId IdType="pubmed">31803858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salama G, Morad M. Merocyanine 540 as an optical probe of transmembrane electrical activity in the heart. Science. 1976;191:485–487.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1082169</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barlow CH, Chance B. Ischemic areas in perfused rat hearts: measurement by NADH fluorescence photography. Science. 1976;193:909–910.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">181843</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsien RY. New calcium indicators and buffers with high selectivity against magnesium and protons: design, synthesis, and properties of prototype structures. Biochemistry. 1980;19:2396–2404.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6770893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Efimov IR, Rendt JM, Salama G. Optical maps of intracellular [Ca2+]i transients and action potentials from the surface of perfused guinea pig hearts. Circulation. 1994;90:1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salama G, Lombardi R, Elson J. Maps of optical action potentials and NADH fluorescence in intact working hearts. Am. J. Physiol. Hear. Circ. Physiol. 1987;252:H384–H394.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3812752</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Piccini JP, et al.  Current challenges in the evaluation of cardiac safety during drug development: translational medicine meets the critical path initiative. Am. Heart J. 2009;158:317–326.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19699852</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siramshetty VB, et al.  WITHDRAWN - A resource for withdrawn and discontinued drugs. Nucleic Acids Res. 2016;44:D1080–D1086.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4702851</ArticleId>
            <ArticleId IdType="pubmed">26553801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanton G. Preclinical cardiac safety assessment of drugs. Drugs RD. 2007;8:213–228.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17596108</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>George SA, et al.  Modulating cardiac conduction during metabolic ischemia with perfusate sodium and calcium in guinea pig hearts. Am. J. Physiol. Hear. Circ. Physiol. 2019;316:H849–H861.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6483020</ArticleId>
            <ArticleId IdType="pubmed">30707595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Janse MJ, Kleber AG, Capucci A, Coronel R, Wilms-Schopman F. Electrophysiological basis for arrhythmias caused by acute ischemia. Role of the subendocardium. J. Mol. Cell. Cardiol. 1986;18:339–355.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3712446</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shaw RM, Rudy Y. Electrophysiologic effects of acute myocardial ischemia: a mechanistic investigation of action potential conduction and conduction failure. Circ. Res. 1997;80:124–138.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8978331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baumeister P, Quinn TA. Altered calcium handling and ventricular arrhythmias in acute ischemia. Clin. Med. Insights Cardiol. 2016;10:61–69.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5158122</ArticleId>
            <ArticleId IdType="pubmed">28008297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kovács M, Tóth J, Hetényi C, Málnási-Csizmadia A, Seller JR. Mechanism of blebbistatin inhibition of myosin II. J. Biol. Chem. 2004;279:35557–35563.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15205456</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fedorov VV, et al.  Application of blebbistatin as an excitation-contraction uncoupler for electrophysiologic study of rat and rabbit hearts. Heart Rhythm. 2007;4:619–626.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17467631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dou Y, Arlock P, Arner A. Blebbistatin specifically inhibits actin-myosin interaction in mouse cardiac muscle. Am. J. Physiol. Cell Physiol. 2007;293:C1148–C1153.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17615158</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brack KE, Narang R, Winter J, Ng GA. The mechanical uncoupler blebbistatin is associated with significant electrophysiological effects in the isolated rabbit heart. Exp. Physiol. 2013;98:1009–1027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3734628</ArticleId>
            <ArticleId IdType="pubmed">23291912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kappadan V, et al.  High-resolution optical measurement of cardiac restitution, contraction, and fibrillation dynamics in beating vs. blebbistatin-uncoupled isolated rabbit hearts. Front. Physiol. 2020;11:464.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7264405</ArticleId>
            <ArticleId IdType="pubmed">32528304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Offerhaus JA, et al.  High heart rate associated early repolarization causes J-waves in both zebra finch and mouse. Physiol. Rep. 2021;9:e14775.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7953022</ArticleId>
            <ArticleId IdType="pubmed">33709567</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swift LM, et al.  Properties of blebbistatin for cardiac optical mapping and other imaging applications. Pflug. Arch. 2012;464:503–512.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3586237</ArticleId>
            <ArticleId IdType="pubmed">22990759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anyukhovsky EP, Rosenshtraukh LV. Electrophysiological responses of canine atrial endocardium and epicardium to acetylcholine and 4-aminopyridine. Cardiovasc. Res. 1999;43:364–370.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10536666</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fiset C, Clark RB, Larsen TS, Giles WR. A rapidly activating sustained K+ current modulates repolarization and excitation-contraction coupling in adult mouse ventricle. J. Physiol. 1997;504:557–563.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1159960</ArticleId>
            <ArticleId IdType="pubmed">9401964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ridley JM, Milnes JT, Zhang YH, Witchel HJ, Hancox JC. Inhibition of HERG K+ current and prolongation of the guinea-pig ventricular action potential by 4-aminopyridine. J. Physiol. 2003;549:667–672.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2342986</ArticleId>
            <ArticleId IdType="pubmed">12740430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thomas G, Klatt B, Blight A. Effect of 4-aminopyridine on action potential parameters in isolated dog purkinje fibers. Arch. Drug Inf. 2010;3:19–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2855834</ArticleId>
            <ArticleId IdType="pubmed">20428229</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nattel S, et al.  Dose-dependence of 4-aminopyridine plasma concentrations and electrophysiological effects in dogs: potential relevance to ionic mechanisms in vivo. Circulation. 2000;101:1179–1184.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10715266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koleske, M. et al. Tetrodotoxin-sensitive Navs contribute to early and delayed afterdepolarizations in long QT arrhythmia models. J. Gen. Physiol. 10.1085/JGP.201711909 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6028491</ArticleId>
            <ArticleId IdType="pubmed">29793933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alarcón MML, De Yurre AR, Felice JI, Medei E, Escobar AL. Phase 1 repolarization rate defines Ca2+ dynamics and contractility on intact mouse hearts. J. Gen. Physiol. 2018;150:991–1002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6571993</ArticleId>
            <ArticleId IdType="pubmed">31000581</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bostock H, Sears TA, Sherratt RM. The effects of 4‐aminopyridine and tetraethylammonium ions on normal and demyelinated mammalian nerve fibres. J. Physiol. 1981;313:301–315.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1274452</ArticleId>
            <ArticleId IdType="pubmed">7277221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Noble M, Tseng KC, Li H, Elfar JC. 4-Aminopyridine as a single agent diagnostic and treatment for severe nerve crush injury. in. Mil. Med. 2019;184:379–385.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6433095</ArticleId>
            <ArticleId IdType="pubmed">30901424</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang S, Zhou Z, Gong Q, Makielski JC, January CT. Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. Circ. Res. 1999;84:989–998.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10325236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duan JJ, et al.  Verapamil blocks HERG channel by the helix residue Y652 and F656 in the S6 transmembrane domain. Acta Pharmacol. Sin. 2007;28:959–967.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17588331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dempsey GT, et al.  Cardiotoxicity screening with simultaneous optogenetic pacing, voltage imaging and calcium imaging. J. Pharmacol. Toxicol. Methods. 2016;81:240–250.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27184445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ramanna H, et al.  Increased dispersion and shortened refractoriness caused by verapamil in chronic atrial fibrillation. J. Am. Coll. Cardiol. 2001;37:1403–1407.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11300453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gibson JK, Yue Y, Bronson J, Palmer C, Numann R. Human stem cell-derived cardiomyocytes detect drug-mediated changes in action potentials and ion currents. J. Pharmacol. Toxicol. Methods. 2014;70:255–267.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25219538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salameh A, et al.  The aging heart: changes in the pharmacodynamic electrophysiological response to verapamil in aged rabbit hearts. J. Physiol. Pharmacol. 2010;61:141–151.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20436214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cranefield PF, Aronson RS, Wit AL. Effect of verapamil on the normal action potential and on a calcium dependent slow response of canine cardiac Purkinje fibers. Circ. Res. 1974;34:204–213.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4811074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Samie FH, et al.  A mechanism of transition from ventricular fibrillation to tachycardia: effect of calcium channel blockade on the dynamics of rotating waves. Circ. Res. 2000;86:684–691.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10747005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hensley J, Billman GE, Johnson JD, Hohl CM, Altschuld RA. Effects of calcium channel antagonists on Ca2+ transients in rat and canine cardiomyocytes. J. Mol. Cell. Cardiol. 1997;29:1037–1043.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9152864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deng YL, et al.  Verapamil suppresses cardiac alternans and ventricular arrhythmias in acute myocardial ischemia via ryanodine receptor inhibition. Am. J. Transl. Res. 2017;9:2712–2722.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5489875</ArticleId>
            <ArticleId IdType="pubmed">28670363</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stokke MK, et al.  ICaL inhibition prevents arrhythmogenic Ca2+ waves caused by abnormal Ca2+ sensitivity of RyR or SR Ca2+ accumulation. Cardiovasc. Res. 2013;98:315–325.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23417043</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barlow CH, Harken AH, Chance B. Evaluation of cardiac ischemia by NADH fluroescence photography. Ann. Surg. 1977;186:737–740.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1396508</ArticleId>
            <ArticleId IdType="pubmed">203234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cathey B, et al.  Open-source multiparametric optocardiography. Sci. Rep. 2019;9:721.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6346041</ArticleId>
            <ArticleId IdType="pubmed">30679527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ratzlaff EH, Grinvald A. A tandem-lens epifluorescence macroscope: hundred-fold brightness advantage for wide-field imaging. J. Neurosci. Methods. 1991;36:127–137.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1905769</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
